Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287745 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL5232224 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL7852751 | 0.97 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL7852754 | 0.97 | ALDH1A1 (0.48) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL30915181 | 0.95 | DRD2 (0.54) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL13419542 | 0.95 | DRD2 (0.54) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL31333941 | 0.88 | DRD2 (0.46) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL13623221 | 0.88 | DRD2 (0.49) | ALDH1A1MAPTDRD2PIM1PIM3 | |
| SCHEMBL31334849 | 0.88 | DRD2 (0.54) | ALDH1A1MAPTLMNADRD2THRB | |
| SCHEMBL12836001 | 0.86 | LMNA (0.54) | ALDH1A1MAPTLMNADRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822495-B2 | Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments | SANOFI (FR) | 2014-09-02 | — | — | US | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | ASTRAZENECA AB (SE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264403-A1 | NOVEL AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | MCHR1, MRGPRX1, MRGPRX4 | ALDH1A1 1961/4885MAPT 4710/4885LMNA 2658/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | ALDH1A1 2263/4885MAPT 4713/4885LMNA 2990/4885 |
| US-20030207899-A1 | Heterocyclylaminomethyloxazo-lidinones as antibacterials | HDHD5, CYP8B1, LSS | ALDH1A1 1293/4885MAPT 4853/4885LMNA 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.